This is good news: the stocks of Moderna and BioNTech have fallen to below $ 100 a share for the first time, and these companies are down around 80 percent from their flying high period of 2021. The demand for the mRNA shots has crashed. And the mRNA vax technology for the flu and RSV have run into problems, as trials are showing adverse effects as has been seen with the Covid vaxxes.
Hopefully this is a major paradigm shift in reality, and not a temporary reprise. We need some wins in this area!
https://alexberenson.substack.com/p/wall-street-is-finally-in-on-the
“It couldn’t have happened to a nicer bunch of medical billionaires.
Investors are voting on the failure of mRNA technology with their feet, fleeing the stocks of Moderna and BioNTech, the two companies that had the greatest wins on the mRNA Covid jabs.
In 2021 and 2022, Moderna and BioNTech rode Covid to tens of billions of dollars in profits. That gravy train is over.
Today, shares in Moderna and BioNTech fell below $100 a share for the first time since the jabs came to market in 2020, plunging almost 10 percent after BioNTech reported weak second-quarter sales and said it would reduce its planned research spending.
Both companies are down almost 80 percent from their 2021 peaks. Pfizer, which markets BioNTech’s mRNA jab and shares profits equally with BioNTech, has also fallen, though not as much, since Pfizer has non-mRNA products.
Behind the plunge: demand for Covid shots has fallen off a cliff worldwide and shows no signs of recovering. Last month, Germany said it expected to throw out 200 million expired shots, more than the total number it has administered.
A few months ago, Pfizer predicted that 100 million Covid jabs would be administered in the United States in 2023. Pfizer’s executives no doubt expected that estimate was conservative, given that publicly traded companies would much rather surprise investors with good news than bad news.
But Pfizer disclosed last week that only about 12 million shots have been given so far - and most came very early in the year. “The 12.4 million doses are behind our earlier projections,” Pfizer chief executive Albert Bourla acknowledged on a conference call last week. (Full disclosure: I am suing Bourla as part of Berenson v. Biden.)
Meanwhile, efforts to expand mRNA technology to jabs to prevent the flu and RSV are faltering. Large clinical trials suggest that the mRNA shots for those illnesses cause serious side effects at the same rate as they do for Covid.
But RSV is very mild compared to Covid, even the Omicron variant. And flu shots that are much less likely to cause serious side effects than the mRNAs have been around for generations. So why would anyone want mRNA jabs for either the flu or RSV - even if they manage to pass regulatory approval?